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Abstract
As treatment for HIV improves, an ageing population is experiencing comorbidity which often leads to complex clinical
presentations requiring an interdisciplinary care approach. This study sought to quantify clinician assessment of the level
of clinical complexity, through the development of a rating scale for people living with HIV (PLHIV), to improve client
care through an interdisciplinary care model. An existing alcohol and other drug complexity rating scale was selected
and modified for use with PLHIV. HIV-specific items were included through consultation with an interdisciplinary team.
A risk-prediction model was developed and validated using clinician ratings of clients attending The Albion Centre,
a tertiary HIV clinic in Sydney, Australia, resulting in the development of the Clinical Complexity Rating Scale for HIV
(CCRS-HIV). Multivariable logistic regression models identified eight characteristics based on clinician assessment of
complexity in PLHIV: financial instability, social isolation, problematic crystal methamphetamine use, mental illness
and/or other problematic substance use, cognitive/neurological impairment, polypharmacy, current hepatitis C infection
and/or cancer, and other physical health comorbidity. A weighted risk-prediction model was developed and validated.
The final model accurately predicted 85% of complex clients, with a sensitivity of 80% and specificity of 91%. This study
developed an HIV-specific clinician-rated complexity scale. Further investigations are required to validate the CCRS-HIV
with broader HIV populations. This simple complexity screening tool is a promising adjunct to clinical assessment to
identify clients with complex physical and psychosocial needs who may benefit from interdisciplinary care interventions
and allocation of resources.
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Introduction
HIV medical treatment has advanced significantly,
reshaping HIV management. These advances improve
viral suppression, such that life expectancy for people
living with HIV (PLHIV) is approaching that of the
general population.1 With the potential to manage
HIV as a chronic health condition, comorbidity from
other challenging chronic medical and psychosocial
conditions can have a significant impact on retention
in care and quality of life (QoL).2
Concurrent chronic physical (e.g. other physical
diagnoses and associated treatments) and psychosocial
(e.g. psychological, social and economic circumstances,
and stigma) conditions complicate client presentations,
particularly within the public health domain.3 HIV
primarily impacts marginalised and often stigmatised
communities where the mental health burden is
higher than the general population,4,5 and HIV can
compound this inequity.6 Discrimination, stigma,
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poor mental health, substance misuse and QoL, and
social isolation have all been shown to have a negative
impact on HIV health outcomes, including poor adher-
ence to antiretroviral therapy (ART), poor retention in
care and mortality.7–12
Older age has also shown to be a significant factor
affecting HIV outcomes and is associated with poorer
clinical outcomes and a higher mortality rate, with a
16 times risk of death within first year of diagnosis in
those aged 50 years or older.13 Ageing in PLHIV is
associated with social isolation, loneliness, stigma and
increased risk of mental illness.14 Identifying risk fac-
tors for comorbidity and frailty, and easy identification
of client complexity, has become a clinical care priority.
It is evident, therefore, that PLHIV, particularly those
with past prolonged immunodeficiency, have complex
care needs as they age.
Studies of client complexity in HIV care have sug-
gested that primary care providers are better able to
identify client complexity compared with rule-based
systems, such as identifying the number of comorbid
diagnoses.3 Multifactorial interactions of comorbid
diagnoses can impact a person’s capacity to effectively
manage HIV infection, including adherence to ART
or appointment attendance. Two issues arise from
complexity issues within HIV care. First, clients who
disengage from care have difficulties suppressing HIV
and are at risk of life-threatening HIV complications15
and transmitting the virus. Second, QoL can be
adversely affected irrespective of HIV suppression if
comorbidity issues are not addressed.
Current research reflects a general consensus that
interdisciplinary care improves outcomes for clients
with chronic and/or comorbid health conditions.16,17
The investigation of the clinical and economic effec-
tiveness of interdisciplinary care for complex health
conditions is an emerging research field. A recent
Cochrane review18 concluded that there is currently
insufficient evidence to definitively interpret the
impact of interdisciplinary interventions; however,
compared with usual care, interdisciplinary care of
complex clients can improve elements of disease con-
trol and service delivery at a modestly increased
cost,17 supporting the development of a holistically
healthy population of PLHIV. In terms of the experi-
ence of interdisciplinary care, clients report enhanced
satisfaction and improved health outcomes while
health workers report enhanced job satisfaction,
greater role clarity and enhanced well-being at
work.19 Much of the literature reviewed here was con-
ducted in the United States, and there is a paucity of
Australian-based research. Furthermore, there is no
validated clinician-administered rating scale to identi-
fy clinical complexity in HIV.
Risk-prediction models offer a mechanism to iden-
tify risk factors and their role on potential out-
comes.20 To determine effective treatment plans,
including developing an appropriate schedule of atten-
dance, clinicians routinely make assessments about the
degree of intervention and resource allocation
required based on clinical complexity of clients.
There is also benefit in proactively identifying poten-
tial risk factors rather than reacting once comorbidity
has already impacted on HIV management. The pri-
mary aim of the present study was to quantify the
components of specialised HIV clinician assessments,
to develop and validate a simple screening tool.
Clinicians determine treatment plans and appointment
schedules based upon their assessment of clients’
health care needs and capacity to adhere to a regimen.
Inherent in this assessment is an estimation of the
degree and impact of client comorbidity and clinical
complexity. This methodology has been used in pre-
vious studies3 seeking to quantify clinician assessment
to improve patient outcomes.
Methods
Development phase
The Albion Centre (Albion) cohort of 1125 regular
PLHIV clients was divided into a development data-
base (n¼ 189) and a validation database (n¼ 936).
During the initial phase of the study, two attending
medical officers (AMOs) at Albion assessed their
clients who had attended for a medical review over a
nine-month period. Both AMOs had over 20 years’
experience working with PLHIV. Each client was
assessed as ‘complex’ or ‘not complex’ by their respec-
tive AMO, based on the clinician’s long-term knowledge
of the clients. For the purpose of the present study,
‘complexity’ was defined as ‘the presence of comorbidity
currently impairing functioning, and potentially warrant-
ing an interdisciplinary team response’.
An existing rating scale comprising nine items and
used in drug and alcohol settings, the Clinical
Complexity Rating Scale (CCRS),21 was adapted.
This scale had a mixed binary and non-binary scoring
system and was not specifically assessing functional
impairment; therefore, the scoring was modified to
ensure it was binary, to have consistency across varia-
bles, and the definitions were adapted to specifically
address the issue of functional impairment. Clinicians
from different disciplines (medical, nursing and psy-
chology) independently identified further HIV-specific
items which were of conceptual interest. An additional
eight HIV-specific items were added to form a compos-
ite scale. All 17 items are listed in Table 1.
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Of this cohort, 16% were considered ‘complex’
according to clinician assessment and were subsequent-
ly rated across the 17 variables (Table 1). Definitions of
each variable can be found in Appendix 1. An age- and
sex-matched ‘non-complex’ cohort was identified and
rated in the same way.
The AMOs rated functional impairment according to
each of the 17 variables as a binary code. Non-binary
variables from the original CCRS scale were re-coded in
the analyses, such that ‘0’ denoted ‘the variable did not
cause functional impairment’ and ‘1’ denoted ‘the vari-
able caused functional impairment’. The only exception
to this was ‘polypharmacy’, for which clients received a
score of ‘1’ solely for the presence of this factor (i.e.
being prescribed at least five medications). For the pur-
pose of this study, functional impairment was considered
to be a loss of functional capacity, as a result of the
variable in question, in the context of their everyday
life. AMOs agreed that functional impairment was evi-
dent when any of the complexity items in question were
inhibiting the client’s ability to fully engage in social,
occupational or physical activities, or the AMO believed
the extent to which the client could function in these
domains was significantly reduced as a result of com-
plexity. For example, AMOs agreed that mental health
or substance use issues that impacted the client’s ability
to regularly engage in employment or led to the repeated
request for medical certificates was deemed ‘functional
impairment’. Given scores can, and should, be modified
over time in response to changing client characteristics,
receiving a score of ‘1’ denoted functional impairment
at the time of assessment.
Multivariable logistic regression models were used
to create a predictive model and identify the key vari-
ables of interest. After fitting the univariate logistic
regression models, variables were entered into the mul-
tivariate model if they had a p-value of less than 0.10 in
the univariate analysis. The final multivariate model
was obtained using a forward stepwise approach and
included statistically significant covariates (p< 0.05).
The resulting scale, the Clinical Complexity Rating
Scale for HIV (CCRS-HIV; Appendix 2), comprised
eight variables, four psychosocial and four physical
health variables. The model’s goodness of fit was assessed
using the Hosmer–Lemeshow goodness-of-fit test.22 High
p-values (>0.05) were considered a reasonable fit.
After the final model was identified, a weighted risk-
prediction screening tool was developed by rounding
each regression coefficient (b-coefficient) to the nearest
integer and multiplying by 10. This scoring procedure
has been used in multiple other studies, with statistical-
ly acceptable robustness.20,23 The total CCRS-HIV
score for each client was derived by summing the indi-
vidual weighted risk factor scores. There are precedents
and rationales for the use of summary comorbidity
measures which use weighted scores to assess the pres-
ence of comorbidity.24
Statistically and clinically relevant ‘cut-offs’ to identify
clinically complex individuals with acceptable robustness
and accuracy were determined using the development
dataset. The predictive power of these cut-offs was
assessed using the validation dataset, using standard sta-
tistical measures to determine sensitivity/specificity and
the area under the receiver-operating curve (AUC) to
assess the accuracy of the model and the discriminative
power of the risk-prediction screening tool.
Validation of the screening tool
The purpose of the validation phase of the study was
to confirm whether factors identified during the devel-
opment phase could still be considered significant pre-
dictors of the primary outcome of interest, clinical
complexity. Following identification of the statistically
and clinically relevant variables during the develop-
ment phase, data for the remaining clients accessing
Albion for medical care (n¼ 936) were collected
using the same methodology described above.
During this phase, the remaining AMOs within the
service assessed their clients according to the variables
identified.
Validation of the screening tool was conducted using
the original eight variables and cut-offs determined
during the development phase. All analyses were con-
ducted using Stata statistical software v14.0 (College
Station, TX, USA).
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Results
The total sample (N¼ 1125) was comprised of 1024
(91%) males and 101 (9%) female clients of Albion.
The mean age of clients attending Albion is 48 years
(range 19–88 years). The profile of sex distribution
shown here is consistent with other HIV services in
Australia. Results from the coding across all 17 varia-
bles during the development phase (n¼ 189) are pre-
sented in Table 2. The distributions of these variables
were analysed to provide unadjusted odds ratios to
show the strength of the associations with the primary
outcome, clinician-assessed ‘complexity’.
Deriving the complexity screening tool
Multivariable regression models were conducted
during the development phase to determine the final
model which included four psychosocial factors: finan-
cial instability (adjusted odds ratio [aOR]: 14.78, 95%
CI: 2.62, 83.51); problematic crystal methamphet-
amine use (aOR: 7.05, 95% CI: 1.25, 39.65); mental
illness and/or other problematic substance use (aOR:
4.22, 95% CI: 1.45, 12.27); and social isolation
(aOR: 10.78, 95% CI: 2.47, 47.14), and four physical
health factors: cognitive/neurological impairment
(aOR: 6.19, 95% CI: 1.94, 19.81); polypharmacy
(aOR: 4.27, 95% CI: 1.43, 12.76); current (problem-
atic) hepatitis C infection and/or cancer (aOR: 5.65,
95% CI: 1.47, 21.79); and other physical health
comorbidity (aOR: 5.33, 95% CI: 1.69, 16.76). The
data from the development and validation phases
for the resulting eight variables comprising the
CCRS-HIV are outlined in Table 3, and the scale is
provided in Appendix 2.
Re-fitting these variables for the remaining 936 par-
ticipants during the validation phase was shown to
have good predictive value. High p-values (0.325 and
0.182 for the development and validation models,
respectively) indicated reasonable model fits for both
development and validation cohorts.
Given the consistent results observed between the
development and validation datasets, it was decided
to maintain the model derived during the development
phase as the final model, as this was validated during
the second phase of the study.
Performance of the complexity screening tool
Analyses were conducted to assess the performance of
the model for various cut-offs to identify complexity.
The development and validation dataset results are
summarised in Table 4 and show that high cut-offs
resulted in high specificity, but relatively low sensitivi-
ty. On balance, a cut-off of 40 (total CCRS-HIV score)
was used to determine ‘complex’ presentations with an
acceptable level of statistical precision. Table 4 shows
the final model to determine complexity, balancing
appropriate sensitivity with specificity. During the val-
idation phase of the study, the data were fitted accord-
ing to the cut-offs determined during the development
phase and were shown to have good predictive ability.
The final model accurately predicted 85% of complex
clients, with a sensitivity of 80% and specificity of 91%.
The overall AUC was 95% (95% CI: 92%, 98%) for
the final model, demonstrating high discrimina-
tive power.
Clinicians were consulted regarding the clinical
utility of the scale to identify complexity and
target interventions. Accordingly, a three-tiered ‘traf-
fic light’ system was developed to categorise complex-
ity. As per results in Table 4, a score of 40 or above
was used to classify someone as ‘complex’ (Red)
which determined that this cohort required additional
interdisciplinary interventions, more frequent follow-
ups and more frequently reviewed care plans.
The remaining two tiers were developed to classify
those as ‘not complex’ (Green, score 0–29), and
those with ‘some complexity evident’ (Orange, score
30–39), requiring monitoring and care plans of
lower intensity.
Discussion
The present study is the first, to our knowledge, to
quantify experienced HIV clinician assessment of
clinical complexity and determine the individual
variables which comprise such an assessment.
Higher scores on the CCRS-HIV were associated
with increased prevalence of complexity, which pro-
vides a platform for a more coordinated, enhanced
and targeted interdisciplinary care team approach.
The scale also potentially provides the opportunity
to separately identify physical and psychosocial
comorbidity, which could be useful in directing inter-
disciplinary care.
PLHIV now have a similar life expectancy to that of
the non-infected population due to ART but the inci-
dence of non-AIDS comorbidity and malignancies
amongst PLHIV is increasing.25 Reasons include
mental health and other psychosocial factors, ageing,
ongoing immune activation and inflammation despite
virological suppression,26 high rates of modifiable risk
factors (e.g. smoking) and the long term effects of
ART.27 In addition, PLHIV are vulnerable to stigma,
social isolation and mental health issues. As Albion is
publicly funded, it also has a significant number of
clients who are from culturally and linguistically
diverse (CALD) backgrounds, are isolated, homeless,
and/or have mental health and/or alcohol and other
drug problems.
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Table 2. The distribution of all variables in the development dataset (shaded items denote HIV-specific items added to the origi-
nal scale).
Characteristics N (%) Unadjusted odds ratio (95% CI) p-value
Age
<45 years 53 (27.32) 1
45–54 years 77 (39.69) 1.07 (0.53, 2.15) 0.858
55þ years 64 (32.99) 1.04 (0.50, 2.16) 0.920
Substance use
No 166 (85.57) 1
Yes 28 (14.43) 4.46 (1.72, 11.57) 0.002
Physical health
No 89 (46) 1
Yes 105 (54) 5.18 (2.79, 9.61) <0.001
Mental health
No 104 (53.61) 1
Yes 90 (46.39) 11.51 (5.84, 22.67) <0.001
Cognitive impairment
No 143 (74.48) 1
Yes 49 (25.52) 15.4 (5.75, 41.26) <0.001
Social network
No 147 (76.56) 1
Yes 45 (23.44) 13.0 (4.84, 34.90) <0.001
Home stability
No 166 (86.46) 1
Yes 26 (13.54) 15.67 (3.58, 68.48) <0.001
Financial stability
No 151 (78.65) 1
Yes 41 (21.35) 32.16 (7.48, 138.28) <0.001
Recent prisona
No 181 (94.27) –
Yes 11 (5.73) –
Children aged < 5 years
No 181 (94.27) 1
Yes 11 (5.73) 2.81 (0.72, 10.96) 0.135
CMA use
No 169 (88.02) 1
Yes 23 (11.98) 8.16 (2.34, 28.50) 0.001
Detectable VL
No 150 (78) 1
Yes 42 (22) 0.54 (0.27, 1.10) 0.083
HCV
No 171 (89.06) 1
Yes 21 (10.94) 5.05 (1.62, 15.82) 0.005
Polypharmacy
No 130 (67.71) 1
Yes 62 (31.29) 6.27 (2.94, 13.32) <0.001
Neurological impairment
No 159 (82.81) 1
Yes 33 (17.19) 7.50 (2.75, 20.41) <0.001
Diabetes
No 179 (93.23) 1
Yes 13 (6.77) 2.38 (0.71, 8.00) 0.162
CVD
No 162 (84.38) 1
Yes 30 (15.63) 1.37 (0.63, 3.01) 0.428
Cancer
No 180 (93.75) 1
Yes 12 (6.25) 5.47 (1.16, 25.65) 0.031
CMA: crystal methamphetamine; CVD: cardiovascular disease; HCV: hepatitis C virus.
aModel did not converge.
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Specific rates of non-AIDS comorbidity in our clinic
population are published elsewhere28 and are similar to
the rates within the Australian HIV Observational
Database (an observational cohort study of more than
4000 PLHIV across Australia under routine clinical
care), including rates of psychological disorders such
as depression (35%) and anxiety (18%).29
This highlights that contemporary HIV management
Table 3. Results from multivariable logistic regression analyses for the development and validation datasets.
Development dataset
(AUC [95% CI]: 94% [91%, 97%])
Validation database












Yes 14.78 (2.62, 83.51) 0.002 27 6.86 (3.35, 14.06) 0.000 19
Problematic CMA use
No 1 1
Yes 7.05 (1.25, 39.65) 0.027 20 26.57 (10.07, 70.07) 0.000 33
Mental illness and/or other
problematic substance use
No 1 1
Yes 4.22 (1.45, 12.27) 0.008 14 3.83 (2.20, 6.67) 0.000 13
Social isolation
No 1 1
Yes 10.78 (2.47, 47.14) 0.002 24 10.72 (5.66, 20.63) 0.000 24
Cognitive/neurological impairment
No 1 1
Yes 6.19 (1.94, 19.81) 0.002 18 3.66 (1.19, 10.67) 0.023 13
Polypharmacy
No 1 1
Yes 4.27 (1.43, 12.76) 0.009 15 4.12 (1.98, 8.57) 0.000 14
Current HCV infection and/or cancer
No 1 1
Yes 5.65 (1.47, 21.79) 0.012 17 8.95 (3.26, 24.62) 0.000 22
Other physical health comorbidity
No 1 1
Yes 5.33 (1.69, 16.76) 0.004 17 4.53 (2.51, 8.21) 0.000 15
AUC: area under the receiver-operating curve; CMA: crystal methamphetamine; HCV: hepatitis C virus.
Table 4. Performance of the development and validation models (shaded line denotes chosen cut-off).
Development model Validation model
AUCa: 95% (95% CI: 92%, 98%) AUCa: 95% (95% CI: 92%, 98%)













Green (not complex) 0–29 >25 98 78 88 90 87 87
Orange (some complexity
evident – requires monitoring)
30–39 >30 98 79 89 82 91 90
>35 85 89 87 76 93 90
Red (complex – requires
integrated care and support)
40 >40 80 91 85 72 95 83
>45 76 91 83 66 95 80
>50 67 95 81 60 96 77
aAUC: area under the curve for score as a continuous variable.
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has moved away from treating the virus alone to encom-
passing the psychosocial and lifestyle factors of clients.
Thus, it is important to have available a validated com-
plexity screening tool to identify those clients who require
more intense interdisciplinary care, support and follow-
up. Not only does this attend to all the health needs of the
client but it also feeds back into the maintenance of viro-
logical suppression by ensuring clients’ adherence to
ART and prevention of transmission of HIV.
This study has developed a valid and standardised
scale of clinician-rated complexity in PLHIV that can
be used to guide interdisciplinary HIV management.
The scale allows any member of the clinical team to
detect complexity with accuracy similar to that of a
specialist HIV physician. By identifying specific, mea-
surable factors, the scale may further assist in the
development of interventions that will potentially
maximise retention in care. As all members of the
clinical team can see a client’s complexity score, it
provides more opportunity for interdisciplinary
engagement. For example, if a client with a high
score attends to see the Triage Nurse, their score
would trigger an alert to other relevant clinicians;
this allows more opportunistic engagement of vulner-
able clients.
Specific potential intervention strategies are likely
to include: (1) Tailored monitoring programmes
guided by the specific factors identified for individual
clients, (2) development of individualised interdisci-
plinary case management plans and (3) referral for
specific medical and/or psychosocial interventions.
The development of a risk-prediction model such as
this has the benefit of minimising prediction error; it
does not, however, provide evidence of a causal rela-
tionship between variables and the outcome which
might be more useful in determining prevention and
intervention strategies. Further research is needed to
identify whether the combined use of this scale, and
related intervention strategies, contribute to a signif-
icant increase in retention in care and other client
outcomes. Arguably, effective use of such a scale
may prevent negative outcomes of complexity
by alerting the need for intensive care needs as
soon as a client enters a service. In addition, the
use of such scales in conjunction with improved
interdisciplinary care coordination models should
improve QoL and well-being.
To our knowledge this is the first complexity rating
scale in HIV to be based on an Australian population
from a large, publicly funded HIV clinic in metropoli-
tan Sydney. The present clinical setting and diversity of
client presentations lends itself to a more predictive and
appropriate model of client complexity. The scale has
now been incorporated in the state-wide electronic
medical record, allowing clinicians to input data
directly into the model during the client consultation,
identifying areas of need that can be addressed by other
members of the interdisciplinary team. This model can
also be used to further quantify the impact of clinical
interventions over time, for example to measure
changes in a client’s complexity rating following an
intervention. These are some of the advantages of
quantifying complexity and progress within HIV man-
agement, as opposed to prior methods of qualitatively
describing progress.
It is worth noting that similar biomedical models
have been developed for the clinical assessment and
management of HIV clients. Consequently, precedents
do exist for this form of clinician-administered rating
scale,3 even to the extent of using summary (additive)
comorbidity measures,24 which some have suggested
are not ideal.30 An important and contemporary exam-
ple of a clinical tool that is applicable to ageing PLHIV
is the ‘frailty index’ validated by Guaraldi et al.,31
which predicts survival and risk factors for incident
comorbidity that are independent of viral load and
CD4 among PLHIV. Likewise, the Veterans Ageing
Cohort Study (VACS) index32 predicts mortality in a
cohort of veteran PLHIV. The present study, however,
is unique in its development of a tool to screen for
complexity in PLHIV within Australia, and also for
its inclusion of psychosocial as well as medical/physical
health factors. This is especially important to develop a
coordinated and collaborative interdisciplinary
response to holistic care needs.
There are limitations to this research. First, the spe-
cific scoring criteria are not clearly defined for every
item on the tool, which is largely a nominal measure-
ment scale (i.e. requiring yes/no responses). For exam-
ple, the exact clinician-reported threshold of what
constitutes social isolation may not itself be uniform.
Second, it is unclear how representative the sample
population is in relation to the entire Australian HIV
population, given that our clients are predominantly
Caucasian men who have sex with men, living in met-
ropolitan Sydney. However, Albion is one of the larg-
est publicly funded HIV clinics in the state, with at least
40% of the service’s clients come from across the state
and from different socioeconomic and CALD back-
grounds.28 It is therefore reasonable to infer the tool
is sufficiently validated to be used throughout New
South Wales.
A third limitation of the present methodology is
that it is subjective in nature, inherent in quantifying
clinician assessment. Comparing clinician ratings in
specific domains against clinicians’ broad assessment
of whether a client is ‘complex’ or ‘not complex’ can
be argued to be problematic. This, however, is the
reality of clinical consultations, where the clinician is
required to make such assessments regarding a
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person’s complexity in order to determine a course of
treatment, visit schedule and appropriate referrals.
The scale developed in the present study aims to
quantify such an assessment; however, future studies
should seek to validate these assessments against other
more objective measures of complexity. Likewise, cli-
nician assessment of functional impairment is also sub-
jective in the present study. Future research should
consider more objective measure of a loss of function-
al capacity.
The scale primarily identifies accumulative scores
of issues to represent complexity and may not
account for other factors around clinician engage-
ment, chronicity and acuteness of other comorbidity
and available supports and resources. Complex
trauma and other psychological conditions and their
related behaviours may also be considered the actual
drivers of the symptoms being presented as contrib-
uting to complexity. It is therefore possible that the
present scale does not accurately assess all the rele-
vant factors that impact PLHIV. Future modifica-
tions of the scale could seek to adapt and modify
the variables assessed, as well as assessing the
correlation between clinician and self (client) reported
concerns.
In the present context, ratings relied upon prior
knowledge of existing clients for clinicians to appropri-
ately estimate the extent of their comorbidity.
However, it is also possible for the scale to be utilised
during an initial consult and can be used to target clin-
ical assessment questions accordingly.
Conclusions
This study demonstrates promising results for the
development and use of a complexity rating scale for
PLHIV. Use of this scale to target clinical interven-
tions, with an increasing move towards proactive
early intervention for non-AIDS comorbidity, is an
important next step. The tool, while validated in its
current form, requires ongoing modification and
review informed by evolving data. It does, however,
provide clinicians with a simple and brief means of
assessing the most relevant non-AIDS comorbidity,
with a view to targeting resources and interventions
accordingly, and can readily be inserted into an elec-
tronic medical record. What makes this model unique
in the field of interdisciplinary HIV care is that it has
potential advantages for both the individual (improve-
ment of general health outcomes) and public health
(enabling adherence to ART and thereby reducing
onward transmission of HIV).
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Consider whether the presence of each variable impacts functioning
The items can be considered in any order
Items 1, 2, 4 and 5 below are psychosocial (PSY) items.
Items 3, 6, 7 and 8 are physical health (PH) items.
Weighted scores are to be added to receive a total score
Variable Definition
Substance use Active substance use impacts functioning
Physical health The presence of physical health conditions impacts functioning
Mental health The presence of symptoms of mental illness impacts functioning
Cognitive impairment Cognitive impairment impacts functioning
Social network Social isolation impedes functioning
Home stability Lack of stable housing impedes functioning
Financial stability Lack of financial stability impedes functioning
Children aged < 5 years The responsibilities for the care of young children impede functioning
Recent prison Recent incarceration impedes current functioning
Crystal methamphetamine (CMA) use Current CMA use is associated with functional impairment
Detectable viral load (VL) Current detectable VL impacts current functioning
Hepatitis C virus (HCV) Current and untreated HCV infection impacts functioning
Polypharmacy The client is prescribed  5 medications
Neurological impairment Current neurological impairment impacts current functioning
Diabetes Current diabetes diagnosis impacts current functioning
Cardiovascular disease (CVD) Current CVD impacts current functioning
Cancer Current cancer diagnosis impacts current functioning
Definitions of each of the 17 variables assessed during the development phase of the study. Scoring denotes evident functional impairment based on




1 Is there problematic crystal methamphetamine (CMA) use which impacts
functioning?
2 Does mental illness (including other problematic substance use, not
CMA) impact functioning?
3 Are there any cognitive/neurological concerns (including HAND) which
impact functioning?
4 Does social isolation impact functioning?
5 Does financial instability impact functioning?
6 Does the client take five or more medications (polypharmacy)?
7 Is there a current hepatitis C virus (HCV) and/or cancer diagnosis which
impacts functioning?
8 Does any other physical comorbidity (not HCV or cancer) impact
functioning?
Total
1274 International Journal of STD & AIDS 30(13)
